The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
 
Patrick Walsh McGarrah
No Relationships to Disclose
 
Shruthi Naik
Employment - Vyriad
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
 
Kah Whye Peng
Employment - Vyriad
Stock and Other Ownership Interests - Vyriad
 
Stephen J. Russell
Employment - Vyriad
Leadership - Vyriad
Stock and Other Ownership Interests - Vyriad
 
Julian R. Molina
No Relationships to Disclose
 
Alex A. Adjei
Consulting or Advisory Role - EMD Serono; Janssen; Mirati Therapeutics; Swiss Rockets; Zai Lab
Research Funding - Bayer Schering Pharma (Inst); I-Mab (Inst); Jacobio (Inst); Kura Oncology (Inst); Merck KGaA (Inst); Tesaro (Inst); Zai Lab (Inst)
(OPTIONAL) Uncompensated Relationships - Merck KGaA; Swiss Rockets; Zai Lab